Open-Label Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral MGCD265 Administered With Interruption to Subjects with Advanced Malignancies

Trial Profile

Open-Label Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral MGCD265 Administered With Interruption to Subjects with Advanced Malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jan 2015

At a glance

  • Drugs Glesatinib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors MethylGene
  • Most Recent Events

    • 16 Nov 2011 Actual patient number (47) added as reported in a MethylGene media release.
    • 14 Nov 2011 Primary endpoint 'Maximum-tolerated-dose' has been met.
    • 14 Nov 2011 Results presented at the 23rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, as reported in a MethylGene media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top